Cytokinetics, Incorporated (CYTK)
| Market Cap | 8.71B +15.9% |
| Revenue (ttm) | 67.67M -21.1% |
| Net Income | -894.00M |
| EPS | -7.18 |
| Shares Out | 139.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,912,762 |
| Open | 62.06 |
| Previous Close | 61.95 |
| Day's Range | 61.84 - 63.61 |
| 52-Week Range | 54.30 - 88.31 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 109.40 (+74.62%) |
| Est. Earnings | Nov 4, 2026 |
About CYTK
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h... [Read more]
Financial Performance
In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price target is $109.4, which is an increase of 74.62% from the latest price.
News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 6...
Cytokinetics price target lowered to $81 from $85 at BofA
BofA lowered the firm’s price target on Cytokinetics (CYTK) to $81 from $85 and keeps a Neutral rating on the shares. The firm updated estimates ahead of Q3 earnings reports…
Cytokinetics announces Health Canada approval of Myqorzo for oHCM treatment
Cytokinetics (CYTK) announced that Health Canada has issued a Notice of Compliance authorizing Myqorzo for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, or oHCM, of New York He...
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (afic...
Cytokinetics initiated with an Outperform at William Blair
William Blair analyst Alethia Young initiated coverage of Cytokinetics (CYTK) with an Outperform rating. Cytokinetics is a commercial-stage specialty cardiology company built around muscle biology and...
Cytokinetics price target lowered to $104 from $115 at UBS
UBS lowered the firm’s price target on Cytokinetics (CYTK) to $104 from $115 and keeps a Buy rating on the shares. Cytokinetics offers an attractive oHCM launch opportunity with nHCM…
Cytokinetics announces additional data from ACACIA-HCM trial at HFSA
Cytokinetics (CYTK) announced that additional data from ACACIA-HCM were presented at the Heart Failure Society of America, or HFSA, annual scientific meeting in Phoenix, Arizona. Data from a prespecif...
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
Cytokinetics price target raised to $113 from $112 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Cytokinetics (CYTK) to $113 from $112 and keeps an Outperform rating on the shares as part of a broader…
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research pres...
Cytokinetics announces start of ASPEN-HCM
Cytokinetics (CYTK) announced the start of ASPEN-HCM, a prospective, multicenter, observational real-world study evaluating Myqorzo in adult patients with symptomatic obstructive hypertrophic cardiomy...
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice
Cytokinetics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted a robust pipeline with MYQORZO's rapid growth in HCM, expansion plans into non-obstructive indications, and a strong Vision 2030 targeting global reach and multiple approvals. Omecamtiv and ulacamten advance heart failure care, supported by a unique culture and strategic partnerships.
Cytokinetics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
MYQORZO's launch is achieving strong momentum, with over 40% new-to-brand share and a goal of exceeding 50% by year-end, supported by physician education, improved market access, and rapid reimbursement. European expansion is underway, and pipeline progress includes upcoming regulatory milestones and a robust heart failure program.
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Cytokinetics Transcript: Citigroup’s Biopharma Back to School Summit 2026
ACACIA-HCM data has positioned MYQORZO for potential regulatory expansion to all HCM patients, with strong commercial momentum in OHCM and preparations for NHCM. The company is also advancing omecamtiv mecarbil in advanced heart failure, with a confirmatory trial designed to optimize outcomes.
Cytokinetics Slides: Corporate presentation
Cytokinetics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Cytokinetics to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following ...
Cytokinetics announces results from ACACIA-HCM, MAPLE-HCM
Cytokinetics (CYTK) announced that additional results from ACACIA-HCM and MAPLE-HCM were presented in a Late Breaking Clinical Session at the European Society of Cardiology, ESC, Congress 2026 in Muni...
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Met...
Cytokinetics Transcript: Investor update
ACACIA-HCM demonstrated that aficamten significantly improved exercise capacity, symptoms, and biomarkers in non-obstructive HCM, with a favorable safety profile and broad benefit across patient subgroups. The results support regulatory submission and may transform treatment for this underserved population.
Cytokinetics Press release: Investor update
Cytokinetics issued a press release on August 28, 2026, disclosing material business information to investors.
Cytokinetics reports ACACIA-HCM trial met both primary endpoints
Cytokinetics (CYTK) announced the primary results from ACACIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy were presented in a ...
Cytokinetics eyes expanded use of heart drug after promising late-stage data
Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no...
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM S...